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Abstract
Background—Full length Tissue factor (flTF) is a key player in hemostasis and also likely 
contributes to venous thromboembolism (VTE), the third most common cardiovascular disease. 
flTF and its minimally coagulant isoform, alternatively spliced TF (asTF), have been detected in 
thrombi, suggesting participation of both isoforms in thrombogenesis, but data on participation of 
asTF in hemostasis is lacking. Therefore, we assessed the role of asTF in flTF cofactor activity 
modulation, using a co-expression system.
Objective—To investigate the interplay between flTF and asTF in hemostasis on endothelial cell 
surface.
Methods—Immortalized endothelial (ECRF) cells were adenovirally transduced to express asTF 
and flTF, after which flTF cofactor activity was measured on cells and microvesicles (MVs). To 
study co-localization of flTF/asTF proteins, confocal microscopy was performed. Finally, 
intracellular distribution of flTF was studied in the presence or absence of heightened asTF levels.
Results—Levels of flTF antigen and cofactor activity were not affected by asTF co-expression. 
asTF and flTF were found to localize in distinct subcellular compartments. Only upon heightened 
overexpression of asTF, lower flTF protein levels and cofactor activity were observed. Heightened 
asTF levels also induced a shift of flTF from non-raft to lipid raft plasma membrane fractions, and 
triggered the expression of ER stress marker BiP. Proteasome inhibition resulted in increased asTF 
– but not flTF – protein expression.
Conclusion—At moderate levels, asTF appears to have negligible impact on flTF cofactor 
activity on endothelial cells and MVs; however, at supra-physiological levels, asTF is able to 
reduce the levels of flTF protein and cofactor activity.
*Corresponding author: h.h.versteeg@lumc.nl (H.H. Versteeg). 
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1. Introduction
Venous thromboembolism (VTE) belongs to the top three most common cardiovascular 
diseases in industrialized nations [1]. VTE mainly comprises deep vein thrombosis and 
pulmonary embolism, which occurs with an incidence rate of approximately 1–2 events per 
1000 individuals per year. Thrombosis is initiated after changes in blood flow, composition 
of blood, and/or damage to the vessel wall, also known as the triad of Virchow [2]. 
Hypercoagulability may be caused by increased microvesicle (MV) levels in blood and is 
associated with VTE in cancer patients, as reviewed elsewhere [3,4].
MVs can be shed via e.g. blebbing of the cell membrane and fall within a size range of 10–
1000 nm [5]. In numerous disease settings these MVs can be shed from platelets, 
monocytes, and/or endothelial cells, and are believed to contribute to pathological processes 
such as cancer and VTE [6]. To date, it is unclear whether MVs are a cause or a consequence 
of VTE. Depending on the origin of the cell, these MVs may contain negatively charged 
phosphatidylserine (PS) and/or Tissue Factor full length form (TF/flTF) in the outside leaflet 
of their lipid bilayer, which increases the procoagulant potential of these vesicles [7].
flTF, a glycosylated transmembrane protein, is the only initiator of the extrinsic coagulation 
cascade in vivo [8], and a key player in thrombosis [3,9]. flTF is also required for vessel 
formation and maturation, as flTF deficiency results in the abrogation of mouse embryonic 
development between days 8.5 and 10.5 due to defects in the yolk sac vasculature [10,11]. In 
2003, the structure of an alternative isoform of TF termed alternatively spliced Tissue Factor 
(asTF), was reported [12]. During TF pre-mRNA processing, exon 5 is spliced out, resulting 
in a frameshift that yields a soluble TF isoform with a unique C-terminal domain. We have 
previously shown that recombinant asTF induces angiogenesis in an integrin-dependent 
manner. asTF binding to αvβ3-integrins promotes endothelial cell migration, while capillary 
formation is induced by asTF via α6β1-integrin activation [13]. In cancer, asTF induces 
tumor growth and metastasis in a β1-integrin dependent manner, and recruits monocytes to 
the tumor stroma [14–16]. asTF also increases the coagulant potential of pancreatic ductal 
adenocarcinoma cells and MVs via an indirect mechanism [17].
Even though asTF promotes cancer progression non-proteolytically, coagulant properties of 
asTF and thus its involvement in thrombosis and/or hemostasis are controversial [18–20]. 
Both flTF and asTF accumulate in occlusive thrombi [21], suggesting a role for asTF in 
thrombus formation. asTF may in principle influence coagulation as it retains the first 166 
residues of flTF critical to forming a complex with FVII(a), including the 165–166 lysine 
doublet involved in the binding of FVII(a) and FX [22,23], but asTF lacks a complete 
binding site for the macromolecular substrates FIX and FX [12,24]. Initial functional studies 
showed that high concentrations of recombinant asTF shorten clotting times in the presence 
of PS-containing phospholipid vesicles [12], but these studies did not uncover how and 
whether asTF influences flTF-dependent clotting. In arterial lipid-rich plaques, the 
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functional activity of asTF likely contributes to thrombus formation in a slow and long-term 
manner; however, in these settings asTF more likely serves to recruit monocytes that 
destabilize the plaque (reviewed in [25]). Another study showed that coagulant activity in 
supernatants from cytokine-stimulated endothelial cells decreased upon asTF depletion [20], 
but again this study did not explore whether asTF and flTF may synergize, or alternatively, 
have opposing functions in coagulation initiation. Finally, a study by Böing and colleagues 
found that asTF expressed in flTF-null HEK293 cells did not influence coagulation 
initiation, but again, this study did not evaluate the possible effects of asTF on flTF function 
[18].
While the above studies investigated TF isoforms in isolation, in vivo, F3 expression results 
in simultaneous biosynthesis of flTF and asTF. Although the relative abundance of asTF can 
vary widely, asTF is never exclusively expressed [25]. The lack of functional data on TF 
isoform-dependent coagulation activation prompted us to study the effects of flTF/asTF co-
expression on TF cofactor activity of endothelial cells and endothelial cell-derived MVs.
2. Materials and methods
2.1. Reagents
Full-length Tissue Factor (flTF)-specific mouse monoclonal antibody mAb TF9-10H10 and 
alternatively spliced Tissue Factor (asTF)-specific rabbit monoclonal antibody RabMab1 
were described previously [14]. Anti-BiP (C50B12) and anti-GAPDH (14C10) rabbit 
monoclonal antibodies were purchased from Cell Signaling. B-actin (N-21)-specific rabbit 
polyclonal antibody was purchased from Santa Cruz Biotechnology.
2.2. Cell culture and adenoviral transductions
The immortalized human endothelial cell line ECRF was cultured in medium 199 (Life 
Technologies), supplemented with 20% FCS (PAA), 0,5% bovine pituitary extract (Gibco), 1 
ml heparin Na LEO 5000 IE/ml (LEO Pharma Inc.) and Penicillin/Streptomycin in a 5% 
CO2 incubator at 37 °C. ECRF cells were transduced with GFP (mock), flTF (NM_001993) 
and/or asTF (NM_001178096) adenoviral constructs as previously described [26]. Briefly, 
ECRF cells were transduced, and the experiments were performed 2 days later. To induce 
MP shedding, cells were serum-starved [27] in M199 medium for 3 h at 37 °C, after which 
conditioned media was harvested and centrifuged for 5 min at 1,000 ×g to remove cell 
debris. To pellet MVs, the supernatant was spun at 20,000 ×g for 1 h as described [28].
2.3. Adenovirus production
Adenoviral constructs encoding asTF or flTF were generated using AdenoX Expression 
system (Clontech). For large-scale adenovirus production, HEK293 cells were transduced 
with adenoviral constructs for 3–4 days at 37 °C. Cells were freeze-thawed three times, after 
which supernatant was collected and stored at −80 °C. Numbers of viral particles were 
determined via QuickTiter Adenovirus Titer ELISA kit (Cell biolabs).
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2.4. Reverse transcriptase-PCR analysis
Total cellular RNA was isolated with TRIzol (Life Technologies) according to the 
manufacturer’s instructions. 1 μg RNA was converted to first strand cDNA using Super 
Script II kit (Life Technologies). PCR amplifications for β-actin and flTF were performed at 
95 °C for 5 min, 95 °C for 30 s, 56 °C for 30 s, 72 °C for 1 min (25 cycles for β-actin; 29 
cycles for flTF), 72 °C for 10 min. PCR conditions for asTF were performed at 95 °C for 5 
min, 95 °C for 1 min, 61 °C for 1 min, 72 °C for 1 min (40 cycles), 72 °C for 5 min. A 
common asTF/flTF forward primer was used: forward, 5′-
TTACACACAGACACAGAGTGTGA-3′, asTF reverse primer, 5′-
GAATATTTCTTTCTTTCCTGAACTTGAAG-3′, flTF reverse primer, 5′-TTGAACA 
CTGAAACAGTAGTTTTCTCC-3′. The β-actin primers were: forward, 5′-
AAGAGATGGCCCACGGCTGCT-3′, and reverse, 5′-CCTTCTGCATCCTGT CGGCA-3′.
2.5. Western blotting
For western blotting, cells and MVs were lysed in 2× sample buffer (Life Technologies), 
proteins were denatured at 95 °C for 5 min and cell lysates were sonicated for 10 s. For lipid 
raft collection, cells were lysed in Brij58 buffer (50 mM Tris, 150 mM CaCl, 1 mM CaCl2, 1 
mM MgCl2, 1% Brij58), centrifuged for 10 min at 800 ×g to pellet cytoskeletal fractions and 
nuclei, and the supernatant was spun at 16,000 ×g for 30 min to pellet lipid rafts. Lysates 
were loaded on 4–12% Bis-Tris PLUS Gels (Thermo Fischer Scientific) and transferred to 
0.2 μm pore size PVDF membranes. Membranes were blocked in 5% milk/TBST and 
incubated with flTF- or asTF-specific primary antibodies O/N in blocking buffer; mAb 
TF9-10H10 (flTF-speciic), RabMab1 (asTF-speciic) [14]. After multiple TBST washing 
steps, the membranes were incubated with horseradish peroxidase-conjugated secondary 
antibodies for 1 h. Bands were visualized with Western lightning Plus ECL (PerkinElmer) 
on X-ray film (Santa Cruz).
2.6. FXa generation
TF-dependent coagulant activity on the surface of ECRF cells and MVs were performed in 
HBS with 1.5 mM CaCl2. The reaction was started by the addition of 1 nM FVIIa (Novo 
Nordisk) and 50 nM FX (Stago). After 30 min at 37 °C the reaction was quenched, after 
which the generated FXa was measured using the kinetic chromogenic substrate 
Spectrozyme FXa (Sekisui) as described before [26].
2.7. Immunofluorescence
ECRF cells were grown on glass coverslips, transduced with flTF or asTF adenovirus and 
serum starved, as described above. The cells were washed and fixed with 2% formaldehyde 
in PBS for 20 min at RT. In selected experiments, cells were subsequently permeabilized 
with 0.1% Triton-X100 for 5 min and blocked with 5% BSA/PBS for 30 min. Primary 
custom rabbit polyclonal antibody specific for human asTF (pAb-1979) [14] was applied at 
5 μg/ml in the blocking buffer and incubated O/N at 4 °C. The following day, cells were 
incubated with goat anti-rabbit-Alexa488 and Alexa594-conjugated 10H10 for 1 h in the 
dark. Cover-slips were mounted with ProlongGold containing DAPI (Thermo Fischer 
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Scientific) for nuclear staining. Images of immunofluorescently labeled cells were captured 
using a Leica SP5 confocal microscope.
3. Results
3.1. asTF exhibits minimal coagulant activity when expressed in human en-dothelial cells
The role of asTF in coagulation initiation has previously been assessed, but the interplay 
between flTF and asTF has never been elucidated. To gain insight into such an interplay, we 
studied asTF’s effect on TF cofactor function when expressed in endothelial cells. In our in 
vitro model, asTF and flTF antigen levels were much higher compared to those under TNFα 
and LPS stimulation conditions (data not shown). Immortalized endothelial ECRF cells were 
transduced to express asTF and/or flTF and, as expected, expression of the two TF isoforms 
was observed in these cells, both on mRNA (Fig. 1a) and antigen (Fig. 1b) levels. We found 
that flTF expression levels did not significantly alter asTF expression levels, and vice versa. 
Antigen analysis on MVs indicated the presence of flTF, but not asTF, suggesting that asTF 
does not associate with endothelial MVs at appreciable levels (Fig. 1b; upper panel). A 
chromogenic FXa generation assay was performed to address whether asTF influences 
cofactor activity of flTF in an endothelial setting. Mock transduced ECRF cells generated <1 
nM FXa, while asTF expression led to a very minor yet statistically significant increase in 
TF activity (Fig. 1d). flTF-transduced ECRF generated 30 nM FXa after 30 min (Fig. 1c). In 
cells co-expressing asTF and flTF, asTF did not influence flTF cofactor activity. Similar 
results were obtained with MVs shed from these cells, but the levels of TF cofactor activity 
and flTF antigen were lower than those observed in ECRF cells (Fig. 1e). We conclude that 
asTF – by itself and without exogenously added phospholipids –has minimal coagulant 
activity, which is consistent with prior reports on endothelial human asTF [17]; when co-
expressed with flTF, asTF does not significantly alter TF cofactor activity of human 
endothelial cells – neither on cell surfaces, nor on MVs derived from them.
3.2. asTF and flTF proteins do not co-localize in human endothelial cells
It is unknown whether asTF and flTF can physically interact. Therefore, we co-expressed 
asTF and flTF in ECRF cells, and immunofluorescence staining was performed. The 
majority of the flTF pool was found on the surface of plasma membrane, while asTF 
predominantly homed to intracellular ECRF compartments (Fig. 2a). Confocal analysis of 
multiple z-stacks confirmed that asTF and flTF proteins do not co-localize in ECRF cells 
(Supplementary Fig. 1). Similarly, asTF and flTF did not co-localize in cell protrusions 
where MV shedding takes place (Fig. 2b). Lack of co-localization was also observed in 
HUVEC cells when both TF isoforms were co-expressed (Fig. 2c). We conclude that, in 
endothelial cells, asTF and flTF proteins home to distinct sub-compartments and are thus not 
in close proximity to each other.
3.3. Heightened overexpression of asTF reduces flTF expression levels
As we did not observe asTF/flTF protein co-localization, we then studied whether supra-
physiological asTF levels may impact TF cofactor activity. A 3-fold higher dose of asTF 
adenovirus hampered flTF adeno-virus expression when co-transduced with asTF (Fig. 3a. 
left panel). As expected, this decrease in flTF protein levels also yielded a significantly 
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lower FXa conversion rate on endothelial cells and MVs (Fig. 3b and c, and Supplementary 
Fig. 2). Cofactor activity and/or protein levels of flTF were not affected by increasing GFP 
expression (Supplementary Fig. 3), demonstrating that this effect was not due to high protein 
expression and the resultant loading of the ER. To study if FVIIa is sequestered by binding 
to asTF, increasing amounts of recombinant FVIIa were added to the cells and MV; higher 
FVIIa concentrations did not restore TF cofactor activity (Fig. 3d and e). In untransformed 
HUVECs, supra-physiological levels of asTF also lowered flTF-dependent FXa generation 
(Fig. 3f and g). Because of the unaltered asTF protein levels after escalating virus doses, we 
hypothesized that excess asTF protein might be targeted to the proteasome. Inhibition of the 
proteasome showed increased asTF protein levels, while flTF protein levels remained 
unaffected (Fig. 3h). As high asTF levels were cleared by the cells, we gathered that high 
asTF levels were likely to induce stress within the endoplasmic reticulum (ER). Indeed, BiP, 
a marker for ER stress, was upregulated as a consequence of high asTF (co-) expression 
(Fig. 3h). We conclude that heightened overexpression of asTF leads to proteosomal 
degradation of asTF protein, yet not flTF protein, and concomitant ER stress.
3.4. asTF impacts distribution of flTF into non-lipid raft fractions of endothelial cell plasma 
membrane
As flTF protein levels and TF coagulant activity are decreased due to heightened asTF, the 
question emerges as to whether asTF is able to induce changes in flTF sub-compartment 
distribution in the plasma membrane. Therefore, plasma membrane was fractionated into the 
material containing lipid rafts, and that free of lipid rafts. asTF levels were equally 
distributed between raft and non-raft fractions (Fig. 4a, upper panel). asTF localization 
patterns were not changed upon co-expression of flTF. The majority of flTF was found in 
the lipid raft fraction, yet a smaller fraction of the total flTF pool was still present in non-raft 
fractions (Fig. 4a, lower panel). Strikingly, flTF distribution was changed when asTF was 
co-expressed, showing a decrease of flTF protein present in the non-raft fraction (Fig. 4b). 
These results suggest that the decrease in flTF expression, when flTF is co-expressed with 
asTF, can be attributed to asTF-triggered downregulation of flTF present in non-raft 
fractions. Separately, these results suggest that coagulant-active flTF is mostly located in 
non-lipid raft plasma membrane fractions of human endothelial cells.
4. Discussion
In this study, we investigated the interplay between asTF and flTF in coagulation initiation. 
Our data indicate that simultaneous expression of asTF and flTF has no effect on TF 
cofactor activity, but heightened asTF overexpression modulates flTF expression in human 
endothelial cells. We base our conclusions on the following observations: i) low asTF levels 
did not alter flTF cofactor activity on cells and/or MVs; ii) asTF and flTF proteins did not 
co-localize in cellular sub-compartments; iii) heightened levels of asTF decreased the levels 
of flTF protein in non-raft plasma membrane fractions, thereby reducing TF cofactor 
activity.
Previous studies of coagulant properties of asTF are fairly inconclusive [19,20]. This is the 
first study that reports on asTF expressed concomitantly with flTF in an endothelial cell 
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setting, to study asTF’s possible function in hemostasis. While FXa generation on cells 
expressing only asTF was very low, a significantly higher FXa conversion rate was observed 
on asTF expressing cells compared to mock-transduced cells (Fig. 1c and d). Although Fig. 
1d seems to demonstrate a lowered rate of FXa generation by asTF/flTF MVs compared to 
flTF MVs, the slope of the asTF/flTF MVs curve is identical to that of the flTF MVs curve, 
likely revealing an artifact during MV isolation and/or processing; we note that this artifact 
was not consistently observed (Fig. 3c). Western blot analysis on MVs and supernatants 
revealed that asTF is not secreted from non-activated endothelial cells (data not shown). 
Also, stimulation of HUVEC cells with IL-1α did not result in asTF secretion, as previously 
reported by Böing et al. [18]. However, other studies that utilized endothelial or malignant 
cell lines were able to demonstrate asTF in conditioned media and/or plasma of cancer 
patients [14,29]. Up till now, asTF cofactor activity was only observed in cell supernatants 
under inflammatory conditions or in a cancerous setting [17,20]. Thus, it might very well be 
that it is only in unique disease settings, e.g. cancer, that the soluble asTF protein is secreted 
by endothelial cells whereby it can modulate coagulation. Studies to measure the quantities 
of MVs and their phosphatidylserine content will provide insight as to how asTF might be 
involved in direct or indirect modulation of flTF-containing MV shedding/coagulant activity.
When asTF was co-expressed with flTF, asTF did not change total TF cofactor activity. 
When higher adenovirus titers were used, we hardly detected increases in asTF protein 
levels. Only after treatment with a proteasome inhibitor, we observed restored asTF levels 
after overexpression. asTF increased ER stress, as BiP levels were elevated (Fig. 3h). 
Interestingly, it has been shown that overexpression of BiP reduces cofactor activity of flTF 
[30,31]. However, this does not completely explain the reduced FXa conversion rates in 
asTF/flTF co-expressing cells, as we observe reduced flTF protein levels. BiP is an ER 
resident chaperone protein and plays a role in the quality control and folding of proteins. 
The two TF isoforms share the large N-terminal domain, but differ in their relatively small 
C-terminal domains, whereby the highly hydrophobic alpha-helical region is present only in 
flTF. Because asTF already increases ER stress, during protein synthesis BiP may also 
increasingly recognize flTF as an incorrectly folded protein and lock it in an unfolded state 
in the presence of asTF, and this might explain lower flTF expression [32]. These results 
indicate that, like many other alternatively spliced soluble proteins [33], asTF may be an 
unstable protein degraded via a proteasome-dependent pathway.
Our study has an important limitation. The asTF and flTF expression levels used in our 
study exceed those observed after stimulation with inflammatory agents such as TNFa and 
LPS (results not shown). Thus, our model may not fully mimic endothelial cell biology. 
Nevertheless, our intention was not to create a biologically faithful endothelial model with 
physiological asTF and flTF expression levels per se, but to investigate the effects of asTF/
flTF co-expression on total TF cofactor activity. Our finding that supra-physiological asTF 
levels never observed in endothelial cells – even under inflammatory conditions – do not 
influence FXa generation, further supports our conclusion that asTF does not influence TF 
cofactor function in this cell type.
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In conclusion, asTF appears to have a very limited role in normal hemostasis. It has minimal 
cofactor activity and does not alter the cofactor function of flTF expressed in human 
endothelial cells and/or TF+ MVs derived from them.
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Characterization of asTF and flTF in ECRF cells after adenoviral transduction. A) mRNA 
levels of asTF and flTF were determined in mock-transduced (1), asTF-transduced (2), flTF-
transduced (3) and asTF/flTF transduced cells (4) via RT-PCR. B) asTF and flTF protein 
expression in cell lysates and MVs assessed using western blot. Odd numbers represent total 
lysates, and even numbers – MVs. C) and E) FXa generation on cells and MVs in the 
presence of 1 nM FVIIa and 50 nM FX. D) and F) Bar graphs represent FXa generation on 
mock (black) versus asTF (grey) ECRF cells and MVs. (*p < 0.05).
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asTF and flTF do not co-localize when concomitantly expressed. A) After transduction, 
ECRF cells were fixed and stained with pAb-1979 (asTF, green) and 10H10 (flTF, red). A 
10-fold magnified image (right panel) shows asTF and flTF in different cellular sub-
compartments. B) Localization of asTF/flTF in cellular protrusions. C) asTF and flTF 
localization in HUVEC cells.
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The effects of supra-physiological asTF levels on TF cofactor activity. A) Western blot 
analysis of total lysates of mock (1), asTF (2), flTF (3) and asTF/flTF transduced (4) ECRF 
cells. Cells were incubated for 12 h with 5 μM MG132, to inhibit the proteasome. B) and C) 
FXa generation on cells and MVs in the presence of 1 nM FVIIa and 50 nM FX. D) and E) 
FXa generation on flTF and asTF/flTF cells and their MVs in the presence of 1 nM, 5 nM or 
25 nM FVIIa and 50 nM FX. F) and G) FXa generation on HUVEC cells and MVs with 
heightened overexpression of asTF, respectively. H) Western blot analysis for the ER-stress 
marker BiP in ECRF cells and asTF (1), flTF (2), and asTF/flTF (3) transduced cells.
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Effects of asTF expression on sub-cellular distribution of flTF, A) Protein levels of asTF (1), 
flTF (2) and asTF/flTF (3) transduced cells in lipid raft fraction, non-raft fraction, 
cytoskeleton, and total cell lysate. B) The flTF ratio in non-raft versus raft fractions in the 
absence and presence of asTF, respectively; analysed via ImageJ.
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